[go: up one dir, main page]

GB202202628D0 - Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety - Google Patents

Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Info

Publication number
GB202202628D0
GB202202628D0 GBGB2202628.0A GB202202628A GB202202628D0 GB 202202628 D0 GB202202628 D0 GB 202202628D0 GB 202202628 A GB202202628 A GB 202202628A GB 202202628 D0 GB202202628 D0 GB 202202628D0
Authority
GB
United Kingdom
Prior art keywords
tissue
organic
targeting moiety
specific targeting
novel use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2202628.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Priority to GBGB2202628.0A priority Critical patent/GB202202628D0/en
Publication of GB202202628D0 publication Critical patent/GB202202628D0/en
Priority to PCT/GB2023/050424 priority patent/WO2023161648A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB2202628.0A 2022-02-25 2022-02-25 Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety Ceased GB202202628D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2202628.0A GB202202628D0 (en) 2022-02-25 2022-02-25 Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety
PCT/GB2023/050424 WO2023161648A1 (en) 2022-02-25 2023-02-24 Novel use and method comprising il-2 and a tissue- or organ-specific targeting moiety

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2202628.0A GB202202628D0 (en) 2022-02-25 2022-02-25 Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Publications (1)

Publication Number Publication Date
GB202202628D0 true GB202202628D0 (en) 2022-04-13

Family

ID=81075481

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2202628.0A Ceased GB202202628D0 (en) 2022-02-25 2022-02-25 Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Country Status (2)

Country Link
GB (1) GB202202628D0 (en)
WO (1) WO2023161648A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094605A2 (en) * 2000-06-09 2001-12-13 University Of Florida Research Foundation, Inc. Recombinant aav vectors for gene therapy of obesity
NZ533833A (en) * 2001-12-21 2008-01-31 Salk Inst For Biological Studi Targeted retrograde gene delivery to motor neurons
SG11201404956PA (en) * 2012-02-17 2014-09-26 Philadelphia Children Hospital Aav vector compositions and methods for gene transfer to cells, organs and tissues
US20190038774A1 (en) * 2015-01-26 2019-02-07 The Research Institute At Nationwide Children's Hospital Compounds, compositions, and methods for using hla-f
CA3085945A1 (en) * 2017-12-19 2019-06-27 The University Of North Carolina At Chapel Hill Methods and compositions for delivery of viral vectors across the blood-brain barrier
GB201912863D0 (en) 2019-09-06 2019-10-23 Babraham Inst Novel method
WO2021127008A1 (en) * 2019-12-16 2021-06-24 The Regents Of The University Of California Compositions and methods for treating neuromuscular disorders

Also Published As

Publication number Publication date
WO2023161648A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
ES3055139T3 (en) Protective apparatus
GB202202628D0 (en) Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety
IL321083A (en) Advanced rna targeting (arnatar)
EP4132666A4 (en) A game apparatus
GB202118073D0 (en) Novel method and composition comprising IL-2 and a tissue- or organ-specific targeting moiety
IL320218A (en) Small interfering rna targeting c3 and uses thereof
GB202215847D0 (en) Part of a protective apparatus and protective apparatus
CA3285442A1 (en) Guide rna and use method thereof
CA3273709A1 (en) Targeting sortilin
CA231644S (en) Mallet
CA232452S (en) Sculpture
CA3210303A1 (en) Blasting
UA160926U (en) Electromagnetic-acoustic transducer
HK40084774A (en) Cytokine il-2 prodrugs comprising a cleavable linker
GB202307777D0 (en) Method and kit-of-parts
GB202509301D0 (en) A protective device
GB202302887D0 (en) Rna
ZA202213833B (en) A protective device and assembling method
GB202505382D0 (en) A self-contained construction device
AU2025902185A0 (en) Backyard Footy Marking Trainer
HK40074822A (en) Il-2 cytokine prodrugs comprising a cleavable linker
GB202411006D0 (en) Protective material
GB202510177D0 (en) Improved signage
CA3280206A1 (en) Tamping tool
AU2024902367A0 (en) Eyelash Protectors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)